Open

Coming up

Don't miss

Replay


LATEST SHOWS

MEDIAWATCH

US media reacts to ebola scare

Read more

DEBATE

How to Stop Ebola: Center for Disease Control Confirms First Case of Virus in US (part 2)

Read more

DEBATE

How to Stop Ebola: Center for Disease Control Confirms First Case of Virus in US

Read more

THE INTERVIEW

I will support Hillary Clinton, will.i.am tells France 24

Read more

FOCUS

Germany: Spread of radical Islam propaganda sparks concerns

Read more

ENCORE!

Corrie Nielsen: Up and Coming Talent at Paris Fashion Week

Read more

FACE-OFF

French Senate election: A new blow for Hollande

Read more

ENCORE!

Encore's Film Show: Julie Gayet, Denzel Washington, and cartoon madness

Read more

MIDDLE EAST MATTERS

Turkey's strategy towards the Islamic State group

Read more

Researchers zero in on Alzheimer's plaque origin

Latest update : 2008-04-09

Researchers have found a key ingredient, produced by a brain cell activity, for the formation of Alzheimer's plaques.

Researchers have found that a key ingredient for the formation of Alzheimer's plaques is produced by a brain cell activity, according to a study that helps understand the disease's origin.

The ability of brain cells to absorb substances from their surface, a process called endocytosis, is essential to producing amyloid beta, a protein fragment that clusters together to form Alzheimer's plaques, said the study released Wednesday.

The researchers found that by giving a drug that blocks endocytosis to a mouse with Alzheimer's disease, levels of amyloid beta sank by 70 percent, according to the study published in the journal Neuron.

But using the drug to treat Alzheimer's is not an option because brain cells need to be able to take in substances from the surface, said the neuroscientists at Washington University School of Medicine in St. Louis.

"Blocking endocytosis isn't a viable option for treatment because cells throughout the body, including brain cells, need endocytosis for healthy function," said the study's first author, John Cirrito, research instructor in neurology.

"But we are starting to understand the origins of amyloid beta in more detail now, and what we're learning is opening other options we can pursue to seek new treatments for Alzheimer's disease," he said.

The researchers believe the brain cells may be accidentally taking in amyloid precursor protein (APP), which breaks down into amyloid beta.

In that case, they said, a drug that reduces APP intake could help reduce production of amyloid beta.
 

Date created : 2008-04-09

COMMENT(S)